Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.58 |
| ▸ | POLB | P06746 | 2/20 | 0.57 |
| ▸ | GAA | P10253 | 2/20 | 0.56 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.54 |
| ▸ | RAB9A | P51151 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 3/20 | 0.53 |
| ▸ | HPGD | P15428 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 3/20 | 0.52 |
| ▸ | MEN1 | O00255 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | RECQL | P46063 | 2/20 | 0.50 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9979145 | 0.87 | KMT2A (0.56) | KMT2APOLBNLRP3LMNAMAPT | |
| SCHEMBL9979203 | 0.85 | KMT2A (0.55) | KMT2APOLBNLRP3LMNAMAPT | |
| SCHEMBL10695522 | 0.84 | KMT2A (0.60) | KMT2APOLBNLRP3LMNAMAPT | |
| SCHEMBL13652637 | 0.84 | KMT2A (0.60) | KMT2APOLBNLRP3SMN1; SMN2RAB9A | |
| SCHEMBL31337280 | 0.83 | KMT2A (0.58) | KMT2APOLBNLRP3LMNAMAPT | |
| SCHEMBL7769522 | 0.83 | SMN1; SMN2 (0.68) | KMT2APOLBNLRP3SMN1; SMN2LMNA | |
| SCHEMBL3978692 | 0.83 | KMT2A (0.58) | KMT2APOLBNLRP3LMNAMAPT | |
| SCHEMBL27713876 | 0.81 | POLB (0.59) | KMT2APOLBGAASMN1; SMN2RAB9A | |
| SCHEMBL4960066 | 0.81 | HPGD (0.62) | POLBGAASMN1; SMN2RAB9ALMNA | |
| SCHEMBL2341773 | 0.80 | MAPT (0.58) | KMT2ANLRP3RAB9AMAPTL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115385955-A | Tetrabiarylphosphine ligands and transition metal complexes thereof | 东莞市均成高新材料有限公司 | 2022-11-25 | — | — | CN | disclosed |
| US-20020065315-A1 | Ion channel modulating agents | POSEIDON PHARMACEUTICALS A/S (DK) | 2002-05-30 | — | — | US | disclosed |
| EP-1178963-A1 | ION CHANNEL MODULATING AGENTS | NEUROSEARCH A/S (DK) | 2002-02-13 | — | — | EP | disclosed |
| WO-2000069823-A1 | ION CHANNEL MODULATING AGENTS | NEUROSEARCH A/S (DK) | 2000-11-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020065315-A1 | Ion channel modulating agents | KCNN1, KCNN3, KCNN2 | KMT2A 1603/4885POLB 4808/4885GAA 2260/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.